Sanofi and the Institut Pasteur create four prestigious awards

SanofiSanofi (EURONEXT: SAN and NYSE: SNY) and the Institut Pasteur announced the creation of the Sanofi-Institut Pasteur Awards to encourage scientific excellence in the service of health.

Four hundred and eighty thousand euro (480,000 €) will support four innovative research projects demonstrating real progress in the life sciences and providing answers to major healthcare problems, more specifically in four fields: neglected tropical diseases, vaccine innovation, drug resistance, and therapeutic approaches to ageing and regenerative medicine.

The jury is composed of seven prestigious members: Prof. Peter C. Agre, John Hopkins University, Baltimore, United States, Nobel Prize in Chemistry 2003, Prof. Elizabeth H. Blackburn, University of California, San Francisco, Nobel Prize in Medicine 2009, Prof. Pascale Cossart, Head of the Bacteria-Cell Interactions Unit, Institut Pasteur, Prof. Alice Dautry, President of the Institut Pasteur, Prof. Depei Liu, Vice President of the Academy of Engineering of China and President of the Chinese Academy of Medical Sciences and the Peking Union Medical College, Dr Robert Sebbag, Vice President, Access to Medicines, Sanofi, and Dr Elias Zerhouni, President, Global R&D, Sanofi.

"With these awards, the Institut Pasteur confirms its commitment to the greater interest by encouraging research, notably in conditions affecting the most vulnerable populations and diseases sharply on the rise in the world," said Alice Dautry, President of the Institut Pasteur.

"I am enthusiastic about this collaborative endeavour with the Institut Pasteur which will promote and support research teams capable of making a real difference in the lives of patients and in key areas of public health," said Elias Zerhouni, President, Global R&D of Sanofi. "The Sanofi-Institut Pasteur Awards follow a long-standing partnership between our two organizations."

Candidates can submit their applications by April 20, 2012. The prices will be awarded in November 2012 at the Institute Pasteur in Paris. For further information: www.sanofiinstitutpasteur-awards.com

Sanofi and the Institut Pasteur have a long history of partnership which reflects Louis Pasteur philosophy which states that "Pure research and applied research are not separate entities. Research and its applications are united together as the fruit of the tree is united with the branch that bears it."

The first partnership emerged through the establishment of the dedicated fund "Fighting Parasitic Diseases" which led to the creation of new research teams. Today, Sanofi also sponsors the Center for Integrative Biology of Emerging Diseases (BIME) and collaborates with the Institut Pasteur in the development of new vaccines against infectious diseases.

About the Institut Pasteur
An internationally renowned center of biomedical research, the Institut Pasteur, created in 1887 by Louis Pasteur, is a recognized private non-profit foundation. Its mission is to contribute to preventing and fighting disease in France and around the world, through scientific and medical research, education, and public health activities. About 2600 individuals work on its campus in Paris. In addition to research in the field of life sciences, a significant part of its work is dedicated to the study of infectious, genetic and neurodegenerative diseases as well as certain cancers. The Institut Pasteur is at the heart of an international network comprising 32 institutes on 5 continents. Since its creation, 10 researchers have received the Nobel Prize in Medicine.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]